In 2004, 90Yttrium-labelled ibritumomab tiuxetan, a mAb targeting CD20, was approved following several clinical studies demonstrating its efficacy in non-Hodgkin B-cell lymphoma (NHL) [101,102,103,104]. The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.